

Cost. Sec.
GAU 1812

01/13/98
jc569 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: M. Rankin et al.

Attorney Docket No.: 2849-A

Serial No.: 08/943,776

Group Art Unit: -to be assigned-

Filed: October 3, 1997

Examiner: -to be assigned-

For: Novel Receptor that Causes Cell Death

Dated: January 8, 1998

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

#3 AR
01/27/98
RECEIVED

JAN 22 1998

GROUP 1800

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231
Box Non-Fee

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56 and §1.97, applicants hereby disclose published material known to them which may be material to the patentability of this invention. The published material is listed below and on the attached copy of Form PTO-1449. A copy of the material is enclosed for the convenience of the Examiner. It is respectfully requested that these documents be (1) fully considered by the Examiner during the course of the examination of the application, (2) listed on the "Notice of References Cited" in this application, and (3) printed on any patent issuing from this application.

Published Material:

1. EST NCBI accession number H41522
2. EST NCBI accession number H46374
3. EST NCBI accession number H46211
4. EST NCBI accession number H46662
5. EST NCBI accession number H46424
6. Chinnaiyan et al., *Science* 274:990, 1996
7. Kitson et al., *Nature* 384:372, 1996
8. Marsters et al., *Current Biology* 6:1669, 1996

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: Jan. 8, 1998 Signed: Hance W. Keston

01/13/98
16569 U.S. PTO

Applicants submit that the claims of this application are directed to subject matter which is patentably distinct from the disclosures of the above-cited references. The above-cited documents, made of record by the applicant herein, do not render unpatentable, either alone or in combination, the claims of the subject application. As to any material supplied, applicants do not admit that it is prior art under 35 U.S.C. § 102 or 103, and specifically reserve the right to antedate any such material, as by a showing under 37 C.F.R. § 131 or by another method.

Respectfully submitted,



Patricia Anne Perkins
Agent for Applicant
Registration No. 34,693
Telephone (206) 587-0430

RECEIVED

JAN 22 1998

GROUP 1800

Immunex Corporation
Legal Affairs Department
51 University Street
Seattle, WA 98101